Calliditas Therapeutics AB (publ) - Special Call Transcript
Good morning, and welcome to the Calliditas Therapeutics Expert Perspectives Webinar. (Operator Instructions)
As a reminder, today's event is being recorded and a replay will be made available on the Calliditas' website.
I would now like to turn the call over to your host, Ashley Robinson of LifeSci Advisors. Please go ahead, sir.
Thank you, Sarah, and good morning, and good afternoon, everyone, and thank you for joining us today for the Calliditas Therapeutics key opinion leader perspective webinar on the pathophysiology and treatment of IgA nephropathy in clinical practice. My name is Ashley Robinson from Lifesci Advisors, and I would be introducing the event as well as moderating the question-and-answer session.
As you know, Calliditas is a specialty pharmaceutical company, listed in Stockholm, Sweden, and in the U.S. on NASDAQ. It is focused on identifying, developing and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |